Ohio's Synthetic 7-OH Ban: Natural Leaf Stays Legal

Ohio is the clearest state-level example of 2026's defining regulatory idea: ban the concentrated synthetic 7-OH products, leave natural kratom leaf alone — at least for now. The state's emergency rule, its permanent replacement, and the still-pending natural-leaf question make Ohio the swing state of American kratom policy. Here is where things actually stand.

The Emergency Rule and Its Crucial Clarification

On December 11, 2025, Governor Mike DeWine asked the Ohio Board of Pharmacy to "immediately designate all synthetic kratom compounds and other dangerous compounds derived from the active ingredient in Kratom as illegal drugs through emergency rule." The Board responded the next day — December 12, 2025 — issuing emergency rule OAC 4729:9-1-01.1 against kratom-related products, citing an imminent public-health risk; state officials pointed to more than 200 fatal overdoses linked to synthetic kratom products between 2019 and 2024.

The rule as first issued read broadly enough to alarm the entire market, so the December 16 clarification mattered enormously: the emergency rule "does not apply to isolated mitragynine, including products that are comprised of natural kratom in its vegetation form." In four days, Ohio went from an apparent blanket ban to the natural-vs-synthetic split that would define the year — the same line Florida, Mississippi, Colorado, and eventually the DEA drew (see our 7-OH vs natural leaf pillar).

From Emergency to Permanent

Emergency rules in Ohio expire after 180 days, so the Board of Pharmacy initiated permanent rulemaking on January 6, 2026 — and here the story forked into two tracks:

• Track one — synthetic compounds: the rule placing mitragynine-related compounds (commonly called synthetic kratom, including concentrated 7-OH products) in Schedule I advanced out of the legislature's Joint Committee on Agency Rule Review on April 13, 2026, and took effect in mid-May 2026, replacing the expiring emergency rule. This is now permanent Ohio law.
• Track two — natural kratom: a second rule that would schedule natural kratom in its vegetative form remains under review at the Common Sense Initiative in the governor's office and has not been forwarded to JCARR. Natural leaf remains legal in Ohio while that review continues.

Even the settled track has friction: on June 22, 2026, JCARR called the Board of Pharmacy in to discuss concerns about the synthetic rule's scope and a post-effective-date guidance document — a sign the boundary between "synthetic compound" and "natural product" is still being litigated at the definitional level. Meanwhile, the legislature has its own vehicles: SB 299 (introduced October 2025) and House companion HB 587 would regulate kratom products and businesses with compound limits — the KCPA-style alternative to scheduling natural leaf.

What's Legal in Ohio Right Now

One operational note for Ohio retailers and buyers alike: because the synthetic rule replaced the emergency rule mid-stream, products lawfully shelved under the December 16 clarification needed re-evaluation against the permanent rule's language in May — and the Board's guidance document is the controlling reference for edge cases. When in doubt, the answer is the same document it always is: the batch COA, read against the rule.

For Ohio buyers, the practical rule is the one this site applies everywhere: natural-leaf products with batch-matched COAs showing trace-level 7-OH are on the legal side of both the state rule and the coming federal threshold; anything marketed on 7-OH content is Schedule I in Ohio today. Our buying guide covers the vendor screen in full.

The Definitional Fight Under the Surface

The June 22 JCARR meeting points at the hard problem every threshold-style rule eventually meets: where exactly does "natural" end and "synthetic" begin? The easy cases bracket the field — milled leaf powder is plainly natural, a lab-converted 7-OH isolate tablet is plainly synthetic. The contested middle is extraction: concentrating the plant's own alkaloids, without chemical conversion, produces products whose alkaloid ratios can drift from leaf norms even though nothing non-botanical was created. Ohio's rule language around "mitragynine-related compounds," the December 16 carve-out for "isolated mitragynine," and the post-effective-date guidance document are the state's attempts to draw that middle line — and JCARR hauling the Board in to discuss scope tells you retailers and manufacturers found the drawing ambiguous in practice.

The DEA's federal approach sidesteps the natural/synthetic vocabulary entirely by using a number: 0.050 percent 7-OH dry weight, whatever the production method. Numbers are enforceable in a way adjectives are not, and if Ohio's definitional friction continues, expect pressure to converge on the federal threshold's measured-content approach. For buyers, the practical translation is the same either way: the batch COA's alkaloid panel is the document that answers where any given product sits, in Ohio and everywhere else — which is why alkaloid disclosure anchors the vendor screen in our buying guide.

Why Ohio Is the State to Watch

Ohio is running the threshold model and the ban question simultaneously, in a large state, with the permanent natural-leaf decision still open. If the Common Sense Initiative review kills or shelves the natural-leaf rule and SB 299/HB 587-style regulation advances, Ohio becomes the biggest proof that the split model can hold. If the natural-leaf rule proceeds to JCARR and takes effect, Ohio becomes the tenth full-ban state and by far the largest after Tennessee — and the natural-vs-synthetic distinction loses its most important state laboratory. Either outcome will be cited in every 2027 statehouse debate; we track it in the 2026 landscape guide.